Project Grant R21AI194167
Award Date
6/23/25
Completion Date
5/31/27
Dollars Obligated
$404K
Federal Agency
National Institute of Allergy and Infectious Diseases
Federal Grant Program
93.855
Assistance Type
Project Grant
Place of Performance
Davis, CA, USA
Similar Awards
This $246,000 Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under CFDA 93.855 Allergy and Infectious Diseases Research supports research to investigate the role of lung repair and regeneration pathways in tuberculosis (TB). The award aims to determine the functional role of the bone morphogenetic protein (BMP) signaling pathway in TB control and reactivation, as well as characterize the cellular mechanisms of BMP pathway activation during TB...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $162,000 in funding to The Washington University to conduct research on the role of plasmacytoid dendritic cells (pDCs) in Mycobacterium tuberculosis (MTB) infection. The goal is to characterize pDC function during MTB infection to identify potential pDC-specific therapeutic targets that could lead to host-directed...
This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), supports research to integrate single-cell omics and ancestry-adjusted expression quantitative trait loci (eQTL) mapping to characterize the immune response to tuberculosis (TB). The $517,185 award, with a performance period from Aug 1, 2024 to Jun 30, 2026, will fund the generation of multi-omic data from 225...
This $176,152 Project Grant award from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 - Allergy and Infectious Diseases Research) supports research at Rutgers, The State University of New Jersey to identify new drug targets for treating drug-tolerant strains of Mycobacterium tuberculosis (MTB), the causative agent of tuberculosis (TB). The key objectives are to investigate how alterations in lipid metabolism and specific host environments, including cholesterol-containing...
This federal Project Grant award of $813,373.00 was provided by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855). The funding supports research conducted by Rutgers, The State University of New Jersey to unravel the spectrum of intrabacterial amide hydrolysis and develop new classes of pyrazinoic acid prodrugs against pyrazinamide resistant Mycobacterium tuberculosis. The goal is to characterize diverse...
The federal Project Grant award, ID F31AI179076, was provided by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855). The award, totaling $207,370, supports research conducted by Duke University to uncover novel bacterial elements with importance in mycobacterial granulomas, which are a hallmark characteristic of tuberculosis (TB) disease. Specifically, the research aims to explore how the bacterial sigma...
This Project Grant award of $1,359,316 from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), supports research to investigate the regulation of mistranslation by the tuberculosis-causing bacterium Mycobacterium tuberculosis (MTB). The goal is to understand how MTB uses regulation of translation error rates, or "mistranslation", to survive stressors including antibiotics and the host environment....
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $749,414 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to The Ohio State University for research on the role of macrophage drug efflux pump MDR1 in Mycobacterium tuberculosis (M.TB) pathogenesis. The primary objectives are to: 1) define the role of MDR1 in M.TB survival in macrophages; 2) determine if HSF1 activation or MDR1 inhibition can shorten M.TB sterilization by TB drugs;...
This federal Project Grant award of $787,171 from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) aims to develop novel 1,2,4-triazole and pyrrolidine compounds as potential treatments for tuberculosis (TB). The primary objectives are to demonstrate preclinical proof-of-concept for these compound classes, optimize their pharmacological properties, and investigate their unique mechanism of action compared...
This $737,342 Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) supports the development and validation of advanced imaging technologies to improve the detection and study of Mycobacterium tuberculosis (MTB), the causative agent of tuberculosis (TB). The key objectives are to: 1) Develop new imaging technologies capable of detecting single MTB bacteria in vitro and in vivo; 2) Use...